Abstract: Slide Presentations |


Andrew F. Shorr, MD*; Nadia Haque, PharmD; Charu Taneja, MPH; Carol Manerski, PharmD; Gery Oster, PhD; Katherine Reyes, MD; Marcus Zervos, MD
Author and Funding Information

Washington Hospital Center, Washington, DC


Chest. 2008;134(4_MeetingAbstracts):s15002. doi:10.1378/chest.134.4_MeetingAbstracts.s15002
Text Size: A A A
Published online


PURPOSE:Methicillin-resistant Staphylococcus aureus (S. aureus [SA]) (MRSA) is a major cause of nosocomial pneumonia. However, the burden of MRSA in non-nosocomial pneumonia (e.g., healthcare-associated pneumonia [HCAP], community-acquired pneumonia [CAP]) remains unclear.

METHODS:We retrospectively identified all patients admitted to a large, urban teaching hospital over a 3-year period with non-nosocomial SA pneumonia. Study subjects were identified based on a discharge diagnosis of pneumonia and (within 48h of admission): (1) culture (blood or sputum) evidence of SA; (2) compatible pulmonary imaging study; and (3) signs/symptoms of pneumonia. Subjects with HCAP were identified using established critieria (eg, prior hospitalization within 90d of admission, intravenous antibiotic therapy in preceding 30d, nursing home residency, hemodialysis, etc.); all remaining subjects were designated as CAP.

RESULTS:A total of 244 study subjects were identified (HCAP, n=128; CAP, n=116). MRSA accounted for 45% of all SA pneumonia in CAP vs 61% in HCAP (p=0.015). Although the appropriateness of initial antibiotic therapy was high for both groups, it was higher for HCAP patients (89% vs 70% for CAP, p<0.001). Need for mechanical ventilation and crude mortality were similar for CAP and HCAP. Fewer than 13 % of all MRSA had MIC values to vancomycin (VAN) <1 mcg/ml, and VAN MICs >2 mcg/ml were seen in 15% of those with HCAP vs. 8% of CAP subjects. USA-300 CA-MRSA strain accounted for 42% of MRSA in CAP vs 15% in HCAP (p<0.001).

CONCLUSION:MRSA is prevalent in patients with non-nosocomial pneumonia due to SA, including CAP. Few MRSA pneumonia strains have low MICs to VAN. CA-MRSA represents an emerging pathogen in both CAP and HCAP due to SA.

CLINICAL IMPLICATIONS:Physicians must consider MRSA when evaluating patients with non-nosocomial pneumonia. The changing MICs of MRSA to VAN and the prevalence of CA-MRSA in both CAP and HCAP suggest the need to examine the role for alternatives to VAN.

DISCLOSURE:Andrew Shorr, Grant monies (from industry related sources) Astellas Pharma US, Ortho-MacNeil-Jansen, Pfizer; Consultant fee, speaker bureau, advisory committee, etc. Astellas Pharma US, Ortho-MacNeil-Jansen, Pfizer; No Product/Research Disclosure Information

Monday, October 27, 2008

2:30 PM - 4:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Community-Acquired Pneumonia*: Etiology, Epidemiology, and Outcome at a Teaching Hospital in Argentina
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543